LB PHARMACEUTICALS INC

LBRXNASDAQ

🏆 #1997 by market capEarnings Nov 5US Equity

$44.97▼ $0.36 (−0.79%)

Live

1h▲ 1.0%

24h▼ 0.8%

7d▼ 0.1%

14d▲ 15.3%

30d▲ 39.4%

1y—

🏦Market Cap

$1.29B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $44.48 – $45.61
52-Week Range: $13.36 – $49.14
Volume: $2.23B
Avg Volume: $2.86B
Shares Outstanding: 28.7M
Next Earnings: Oct 22, 2026

Fundamentals Snapshot

Annual Revenue: $147M
Last Q Revenue: $33M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.72
Dividend Yield: —

Why Investors Own LBRX

✓High-growth profile — revenue up +27.4% YoY with expanding US Equity exposure.
✓Healthy economics — 50% gross margin and 4% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$147M▲ +32.2% YoY

Gross Margin (TTM)

50.3%▲ +2.9% YoY

Operating Income (TTM)

$24M▲ +32.2% YoY

Free Cash Flow (TTM)

$6M▲ +32.2% YoY

About LB PHARMACEUTICALS INC

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

🦦

Otter Score Breakdown

ⓘ

💎Quality★★★★★

🚀Growth★★★★★

⚖️Valuation★★★★★

⚡Momentum★★★★★

Overall Score

Weak

41/100

Analyst Ratings

ⓘ

Consensus

Buy

15 analysts

Strong Buy5

Buy9

Hold1

Sell0

Strong Sell0

Ratings as of Aug 2026

Latest News & Updates

🚀

Benzinga·1d ago

LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(1.71) per share which missed the analyst consensus estimate of $(0.80) by 113.75 percent. This is a 87.41 percent increase over losses of $(13.58) per

🛰️

Benzinga·9d ago

HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and maintains $45 price target.

🌌

Benzinga·14d ago

LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded Warrants

LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple

Yahoo·21d ago

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to sc

🛰️

Benzinga·21d ago

LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027

LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple

Yahoo·22d ago